Who Owns Covetrus Company?

Who Owns Covetrus?

Covetrus is a private company owned by Clayton, Dubilier & Rice and TPG after their 2022 take-private deal. It started in 2019 from a merger of Vets First Choice and Henry Schein Animal Health.

That shift matters because ownership now sits with private equity, not public shareholders. For a quick strategy view, see Covetrus PESTEL Analysis.

Covetrus ownership changed fast after its 2019 formation. Today, Covetrus is owned by private equity sponsors, not public market holders, after its 2022 take-private deal.

How Covetrus began

Covetrus company background starts with a 2019 merger of Vets First Choice and Henry Schein Animal Health. That deal created a new public company with a mixed ownership base from both predecessor groups.

Early ownership base

At launch, Covetrus stock ownership sat with public shareholders from the merged businesses. So the early cap table was market driven, not controlled by one single owner.

Public listing era

Covetrus was publicly traded before the buyout, so it had a stock symbol and outside shareholders. That changed in 2022, when the company left the public market.

Who bought Covetrus

Funds tied to Clayton, Dubilier & Rice and TPG bought Covetrus in an all-cash deal valued at about $4.4 billion, or $21.00 per share. This is the key Covetrus private equity owner shift.

Current control

Exact equity percentages are not public, but sponsor control is clear in Covetrus company structure. That means the Covetrus major shareholders are private equity funds and their board appointees.

Why it matters

Private ownership can speed decisions and tighten spending, but it can also raise leverage and service concerns. For a deeper look at the business base, see the Target Market of Covetrus.

Who owns Covetrus today is a sponsor-led answer, not a public shareholder one. Covetrus latest ownership information shows control sits with funds affiliated with Clayton, Dubilier & Rice and TPG, while management may hold rollover equity. The exact Covetrus parent company name is not used in the legal sense here because the company is now privately held and no longer reports a public float.

Covetrus ownership details

Covetrus moved from public ownership to private equity control in one of its biggest shifts. The main question now is not whether Covetrus is publicly traded, but how the sponsor group runs capital, cost, and growth choices.

• Take-private value: $4.4 billion
• Offer price: $21.00 per share
• Deal year: 2022
• Public status: no longer listed
• Control: private equity sponsors
• Ownership split: not disclosed

Covetrus ownership shifted from founder-led software roots to public-company scale and then to private equity control. The 2019 merger with Henry Schein Animal Health changed the business mix, and the 2022 take-private deal by CD&R and TPG removed Covetrus from the public market.

Who owns Covetrus now is simple: it is privately held, so there is no public float, no active stock symbol, and no current public shareholder base. The Covetrus company owners are private equity sponsors, while former public-market Covetrus institutional investors are no longer the core ownership group. For context on the business mix that supports this structure, see Marketing Strategy of Covetrus.

Covetrus ownership and control

Covetrus ownership now sits with private equity, not public shareholders. That means the main focus is execution, cash flow, and operating discipline.

• Who founded Covetrus company: Benjamin Shaw
• Who bought Covetrus: CD&R and TPG
• Is Covetrus publicly traded: No
• Covetrus private equity owner: CD&R and TPG

The Covetrus acquisition history matters because it changed how investors read the brand. Under founder roots, the company carried an innovation-led identity tied to software and recurring pharmacy revenue; after the 2019 merger, it also became a scale and distribution story; after the 2022 buyout, Covetrus stock ownership stopped shaping the narrative. So the market now judges Covetrus company structure by performance, not quarterly public disclosures.

For people asking Who is the parent company of Covetrus or the Covetrus parent company name, the practical answer is that it no longer has a public parent listed on an exchange. Its latest ownership information points to private-equity control, which usually means less reporting and more freedom to make longer-term fixes. That also means Covetrus major shareholders are not public-market holders today, and the old Covetrus stock symbol no longer applies.

Covetrus board of directors is no longer shaped by a public float or retail voting base. After the 2024 take-private deal, Covetrus ownership sits with private-equity owners, so the board now answers mainly to the sponsors and the top management team.

That is the core of Who owns Covetrus: the Covetrus private equity owner group now holds the real voting power, while management focuses on service, product quality, and continuity. The company was taken private in 2024 in an all-cash deal valued at $21.00 per share, so the old Covetrus stock symbol and public proxy process no longer drive strategy. For a quick look at the business model behind that control, see Revenue Streams & Business Model of Covetrus.

Who holds real influence over Covetrus

Covetrus board of directors influence now runs through the private owners, not public investors. That means Covetrus major shareholders can shape financing, executive pay, and deal timing much faster than a listed-company investor base.

• Sponsor nominees likely dominate votes
• Independent directors add oversight
• Management runs daily operations
• Public proxy fights are gone

Covetrus latest ownership information shows a classic private-equity structure, not a public one-share-one-vote setup. Who bought Covetrus matters here because the acquirer group, not Covetrus institutional investors, now sets the pace for Covetrus acquisition history, Covetrus company structure, and the Covetrus parent company name.

Covetrus ownership shifted sharply in 2022 when CD&R and TPG took the company private, ending its public run after the 2019 listing. That move changed the main question from market trading to execution: can Covetrus keep service quality steady while its private equity owner pushes operational change?

The key Covetrus latest ownership information is simple: the company is no longer public, so there is no active Covetrus stock symbol or public float to track. For investors and customers, the real test is whether the Covetrus company structure under private ownership keeps the software, fulfillment, and prescription links reliable. You can see the broader business context in Mission, Vision & Core Values of Covetrus.

Private equity credibility

CD&R and TPG bring capital and operating discipline. That can support a steadier Covetrus parent company setup after the 2022 buyout.

Execution risk stays real

Private ownership can also raise concern about pricing pressure or restructuring. For veterinary customers, service quality still matters most.

From public to private

Covetrus company owners changed in 2022, ending the public era that began in 2019. That is the biggest step in the Covetrus acquisition history.

Trust is the main metric

Brand credibility now depends on delivery, not listings. Veterinary practices will judge the Covetrus ownership details by uptime, fulfillment speed, and prescription flow.